Moreover, the ATM-MT group showed a higher mutation load and stronger antigen-specific immunity than the ATM-WT group in the immunotherapy cohort, TCGA-Bladder cancer cohort and GDSC-Bladder cancer cell line dataset (Figures 3C–F, P < 0.05). The gene discussed is ATM; the disease is urinary bladder carcinoma.